Researchers working with induced pluripotent stem cells have struggled with a few deficiencies that have made the cells less desirable than embryonic stem cells for the treatment of disease. For one thing, says, Popular Science's Rebecca Boyle, iPS cells contain the same mutations as the person they're taken from, and current gene editing techniques to correct these deficiencies have led to cancer in mice and other side effects.